USPTO rejects Celgene bid for Bass sanctions
28-09-2015
Profit is at the heart of every IPR, says Kyle Bass
13-08-2015
Photo: Courtesy of Celgene ( Celgene Logo, https://www.celgene.com/media-library/celgene-logo/)
Pharmaceutical company Celgene has requested that the US Patent and Trademark Office (USPTO) sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review (IPR) petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Celgene; Kyle Bass; Coalition for Affordable Drugs; IPR; PTAB; pharmaceuticals; generics; USPTO
